The unsolved relationship of brain aging and late-onset Alzheimer disease

Biochimica et Biophysica Acta - General Subjects

Volumn 1790, Issue 10, 2009, Pages 1124-1132

  Kern, Andreas ^a   Behl, Christian ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Aging; Alzheimer disease; Amyloid

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; GINKGO BILOBA EXTRACT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; BRAIN ATROPHY; BRAIN REGION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEMENTIA; DEMOGRAPHY; DISEASE CLASSIFICATION; HISTOPATHOLOGY; HUMAN; HYPERTENSION; MILD COGNITIVE IMPAIRMENT; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; RISK FACTOR; SYNAPTIC TRANSMISSION;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; DEMENTIA; FREE RADICALS; HUMANS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES;

EID: 69949107465     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2009.07.016     Document Type: Review

References (183)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
2. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 (1991) 239-259
3. Carter D.B. The interaction of amyloid-beta with ApoE. Subcell. Biochem. 38 (2005) 255-272
4. Lutz W., Sanderson W., and Scherbov S. The coming acceleration of global population ageing. Nature 451 (2008) 716-719
5. C.P. Ferri, M. Prince, C. Brayne et al., Global prevalence of dementia: a Delphi consensus study, Lancet 366 2112-2117.
6. Langa K.M., Chernew M.E., Kabeto M.U., et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J. Gen. Intern. Med. 16 (2001) 770-778
7. Lobo A., Launer L.J., Fratiglioni L., et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 54 (2000) S4-9
8. Kalaria R.N., Maestre G.E., Arizaga R., et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurology 7 (2008) 812-826
9. Levy J.A., and Chelune G.J. Cognitive-behavioral profiles of neurodegenerative dementias: beyond Alzheimer's disease. J. Geriatr. Psychiatry Neurol. 20 (2007) 227-238
10. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., and Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56 (1999) 303-308
11. Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Cummings J.L., and DeKosky S.T. Practice parameter: Early detection of dementia: mild cognitive impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 (2001) 1133-1142
12. Graham J.E., Rockwood K., Beattie B.L., et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 349 (1997) 1793-1796
13. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
14. Hughes C.P., Berg L., Danziger W.L., Coben L.A., and Martin R.L. A new clinical scale for the staging of dementia. Br. J. Psychiatry 140 (1982) 566-572
15. Reisberg B., Ferris S.H., de Leon M.J., and Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am. J. Psychiatry 139 (1982) 1136-1139
16. Burke S.N., and Barnes C.A. Neural plasticity in the ageing brain. Nat. Rev. Neurosci. 7 (2006) 30-40
17. Scahill R.I., Schott J.M., Stevens J.M., Rossor M.N., and Fox N.C. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 4703-4707
18. Jack Jr. C.R., Shiung M.M., Gunter J.L., et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62 (2004) 591-600
19. Ohm T.G., Muller H., Braak H., and Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience 64 (1995) 209-217
20. Nelson P.T., Jicha G.A., Schmitt F.A., et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J. Neuropathol. Exp. Neurol. 66 (2007) 1136-1146
21. Giannakopoulos P., Herrmann F.R., Bussiere T., et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60 (2003) 1495-1500
22. Tiraboschi P., Hansen L.A., Thal L.J., and Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62 (2004) 1984-1989
23. Alafuzoff I., Arzberger T., Al-Sarraj S., et al. Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol. 18 (2008) 484-496
24. Whitwell J.L., Josephs K.A., Murray M.E., et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 71 (2008) 743-749
25. Archer H.A., Edison P., Brooks D.J., et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann. Neurol. 60 (2006) 145-147
26. Silbert L.C., Quinn J.F., Moore M.M., et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 61 (2003) 487-492
27. Josephs K.A., Whitwell J.L., Ahmed Z., et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann. Neurol. 63 (2008) 204-212
28. Neve R.L., and Robakis N.K. Alzheimer's disease: a re-examination of the amyloid hypothesis. Trends Neurosci. 21 (1998) 15-19
29. Naslund J., Haroutunian V., Mohs R., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Jama 283 (2000) 1571-1577
30. Schupf N., Tang M.X., Fukuyama H., et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 14052-14057
31. Thal D.R., Capetillo-Zarate E., Del Tredici K., and Braak H. The development of amyloid beta protein deposits in the aged brain. Sci. Aging Knowledge Environ. 2006 (2006) re1
32. Games D., Adams D., Alessandrini R., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
33. Irizarry M.C., Soriano F., McNamara M., et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17 (1997) 7053-7059
34. Spires T.L., and Hyman B.T. Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2 (2005) 423-437
35. Clayton D.A., Mesches M.H., Alvarez E., Bickford P.C., and Browning M.D. A hippocampal NR2B deficit can mimic age-related changes in long-term potentiation and spatial learning in the Fischer 344 rat. J. Neurosci. 22 (2002) 3628-3637
36. Foster T.C. Involvement of hippocampal synaptic plasticity in age-related memory decline. Brain Res. Rev. 30 (1999) 236-249
37. Rosenzweig E.S., and Barnes C.A. Impact of aging on hippocampal function: plasticity, network dynamics, and cognition. Prog. Neurobiol. 69 (2003) 143-179
38. Engert F., and Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 399 (1999) 66-70
39. de Brabander J.M., Kramers R.J., and Uylings H.B. Layer-specific dendritic regression of pyramidal cells with ageing in the human prefrontal cortex. Eur. J. Neurosci. 10 (1998) 1261-1269
40. Nakamura S., Akiguchi I., Kameyama M., and Mizuno N. Age-related changes of pyramidal cell basal dendrites in layers III and V of human motor cortex: a quantitative Golgi study. Acta Neuropathol. 65 (1985) 281-284
41. Watkins J.C., and Jane D.E. The glutamate story. Br. J. Pharmacol 147 Suppl. 1 (2006) S100-S108
42. Bliss T.V., and Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361 (1993) 31-39
43. Sucher N.J., Awobuluyi M., Choi Y.B., and Lipton S.A. NMDA receptors: from genes to channels. Trends Pharmacol. Sci. 17 (1996) 348-355
44. Liu P., Smith P.F., and Darlington C.L. Glutamate receptor subunits expression in memory-associated brain structures: regional variations and effects of aging. Synapse 62 (2008) 834-841
45. Magnusson K.R. The aging of the NMDA receptor complex. Front. Biosci. 3 (1998) e70-80
46. Beal M.F. Mechanisms of excitotoxicity in neurologic diseases. FASEB J. 6 (1992) 3338-3344
47. Lipton S.A. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J. Alzheimers Dis. 6 (2004) S61-74
48. Heim C., and Sontag K.H. Memantine prevents progressive functional neurodegeneration in rats. J. Neural. Transm. Suppl. 46 (1995) 117-130
49. Weller M., Finiels-Marlier F., and Paul S.M. NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res. 613 (1993) 143-148
50. Bakchine S., and Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J. Alzheimers Dis. 13 (2008) 97-107
51. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., and Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348 (2003) 1333-1341
52. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama 291 (2004) 317-324
53. Minkeviciene R., Banerjee P., and Tanila H. Memantine Improves Spatial Learning in a Transgenic Mouse Model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 311 (2004) 677-682
54. Scholtzova H., Wadghiri Y.Z., Douadi M., et al. Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J. Neurosci. Res. 86 (2008) 2784-2791
55. Geula C., Nagykery N., Nicholas A., and Wu C.K. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J. Neuropathol. Exp. Neurol. 67 (2008) 309-318
56. Goekoop R., Scheltens P., Barkhof F., and Rombouts S.A. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation-a pharmacological fMRI study. Brain 129 (2006) 141-157
57. Gron G., Brandenburg I., Wunderlich A.P., and Riepe M.W. Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis. Neurobiol. Aging 27 (2006) 78-87
58. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163 (2000) 495-529
59. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., and Delon M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215 (1982) 1237-1239
60. Bierer L.M., Haroutunian V., Gabriel S., et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J. Neurochem. 64 (1995) 749-760
61. Ikonomovic M.D., Mufson E.J., Wuu J., Bennett D.A., and DeKosky S.T. Reduction of choline acetyltransferase activity in primary visual cortex in mild to moderate Alzheimer's disease. Arch. Neurol. 62 (2005) 425-430
62. Benjamin B., and Burns A. Donepezil for Alzheimer's disease. Expert Rev. Neurother. 7 (2007) 1243-1249
63. Bryson H.M., and Benfield P. Donepezil. Drugs Aging 10 (1997) 234-239
64. Greenberg S.M., Tennis M.K., Brown L.B., et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch. Neurol. 57 (2000) 94-99
65. Hansen R.A., Gartlehner G., Webb A.P., Morgan L.C., Moore C.G., and Jonas D.E. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin. Interv. Aging 3 (2008) 211-225
66. Knopman D., Boland L.L., Mosley T., et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 56 (2001) 42-48
67. Skoog I., Lernfelt B., Landahl S., et al. 15-year longitudinal study of blood pressure and dementia. Lancet 347 (1996) 1141-1145
68. Whitmer R.A., Sidney S., Selby J., Johnston S.C., and Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64 (2005) 277-281
69. Verghese J., Lipton R.B., Hall C.B., Kuslansky G., and Katz M.J. Low blood pressure and the risk of dementia in very old individuals. Neurology 61 (2003) 1667-1672
70. Hanon O., Latour F., Seux M.L., Lenoir H., Forette F., and Rigaud A.S. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR). J. Nutr. Health Aging 9 (2005) 106-111
71. de Leeuw F.E., Richard F., de Groot J.C., et al. Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 35 (2004) 1057-1060
72. Forette F., Seux M.L., Staessen J.A., et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162 (2002) 2046-2052
73. Tzourio C., Anderson C., Chapman N., et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. 163 (2003) 1069-1075
74. Applegate W.B., Pressel S., Wittes J., et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch. Intern. Med. 154 (1994) 2154-2160
75. Lithell H., Hansson L., Skoog I., et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens. 22 (2004) 1605-1612
76. Prince M.J., Bird A.S., Blizard R.A., and Mann A.H. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. Bmj 312 (1996) 801-805
77. Vanhanen M., Koivisto K., Moilanen L., et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 67 (2006) 843-847
78. Kalmijn S., Foley D., White L., et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2255-2260
79. Sastre M., Klockgether T., and Heneka M.T. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int. J. Dev. Neurosci. 24 (2006) 167-176
80. Pertusa M., Garcia-Matas S., Rodriguez-Farre E., Sanfeliu C., and Cristofol R. Astrocytes aged in vitro show a decreased neuroprotective capacity. J. Neurochem. 101 (2007) 794-805
81. J.E. Simpson, P.G. Ince, G. Lace, et al., Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain, Neurobiol. Aging (in press). doi:10.1016/j.neurobiolaging.2008.05.015.
82. Nagele R.G., Wegiel J., Venkataraman V., Imaki H., Wang K.C., and Wegiel J. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol. Aging 25 (2004) 663-674
83. Beach R.W.T.G., and McGeer E.G. Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia 2 (1989) 420-436
84. Vehmas A.K., Kawas C.H., Stewart W.F., and Troncoso J.C. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol. Aging 24 (2003) 321-331
85. Barger S.W., and Basile A.S. Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function. J. Neurochem. 76 (2001) 846-854
86. Takeuchi H., Jin S., Wang J., et al. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J. Biol. Chem. 281 (2006) 21362-21368
87. Timothy I.F.A., Harrigan J., David Jourd'heuil, and Mongin A.A. Activation of microglia with zymosan promotes excitatory amino acid release via volume-regulated anion channels: the role of NADPH oxidases. J. Neurochem. 106 (2008) 2449-2462
88. Floden A.M., Li S., and Combs C.K. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J. Neurosci. 25 (2005) 2566-2575
89. Andersen K., Launer L.J., Ott A., Hoes A.W., Breteler M.M., and Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45 (1995) 1441-1445
90. Breitner J.C., Gau B.A., Welsh K.A., et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44 (1994) 227-232
91. in't Veld B.A., Launer L.J., Hoes A.W., et al. NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol. Aging 19 (1998) 607-611
92. Martin B.K., Szekely C., Brandt J., et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 65 (2008) 896-905
93. Harman D. The biologic clock: the mitochondria?. J. Am. Geriatr. Soc. 20 (1972) 145-147
94. Moosmann B., and Behl C. Mitochondrially encoded cysteine predicts animal lifespan. Aging Cell 7 (2008) 32-46
95. Reiter R.J. Oxidative processes and antioxidative defence mechanisms in the aging brain. FASEB J. 9 (1995) 526-533
96. Behl C., and Moosmann B. Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic. Biol. Med. 33 (2002) 182-191
97. Moosmann B., and Behl C. Antioxidants as treatment for neurodegenerative disorders. Expert. Opin. Investig. Drugs 11 (2002) 1407-1435
98. Zhu Y., Carvey P.M., and Ling Z. Age-related changes in glutathione and glutathione-related enzymes in rat brain. Brain Res. 1090 (2006) 35-44
99. Cini M., and Moretti A. Studies on lipid peroxidation and protein oxidation in the aging brain. Neurobiol. Aging 16 (1995) 53-57
100. O'Donnell E., and Lynch M.A. Dietary antioxidant supplementation reverses age-related neuronal changes. Neurobiol. Aging 19 (1998) 461-467
101. Mylonas C., and Kouretas D. Lipid peroxidation and tissue damage. In Vivo 13 (1999) 295-309
102. Keller J.N., and Mattson M.P. Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev. Neurosci. 9 (1998) 105-116
103. Markesbery W.R., and Lovell M.A. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch. Neurol. 64 (2007) 954-956
104. Mielke M.M., and Lyketsos C.G. Lipids and the pathogenesis of Alzheimer's disease: Is there a link?. Int. Rev. Psychiatry 18 (2006) 173-186
105. Abd El Mohsen M.M., Iravani M.M., et al. Age-associated changes in protein oxidation and proteasome activities in rat brain: modulation by antioxidants. Biochem. Biophys. Res. Commun. 336 (2005) 386-391
106. Poon H.F., Shepherd H.M., Reed T.T., et al. Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis. Neurobiol. Aging 27 (2006) 1020-1034
107. Rodrigues Siqueira I., Fochesatto C., da Silva Torres I.L., Dalmaz C., and Alexandre Netto C. Aging affects oxidative state in hippocampus, hypothalamus and adrenal glands of Wistar rats. Life Sci. 78 (2005) 271-278
108. Greilberger J., Koidl C., Greilberger M., et al. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic. Res. 42 (2008) 633-638
109. Keller J.N., Schmitt F.A., Scheff S.W., et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64 (2005) 1152-1156
110. Bender A., Krishnan K.J., Morris C.M., et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38 (2006) 515-517
111. Corral-Debrinski M., Horton T., Lott M.T., Shoffner J.M., Beal M.F., and Wallace D.C. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat. Genet. 2 (1992) 324-329
112. Wang J., Markesbery W.R., and Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J. Neurochem. 96 (2006) 825-832
113. Wang J., Xiong S., Xie C., Markesbery W.R., and Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J. Neurochem. 93 (2005) 953-962
114. Hajieva P., and Behl C. Antioxidants as a potential therapy against age-related neurodegenerative diseases: amyloid Beta toxicity and Alzheimer's disease. Curr. Pharm. Des. 12 (2006) 699-704
115. Wengreen H.J., Munger R.G., Corcoran C.D., et al. Antioxidant intake and cognitive function of elderly men and women: the Cache County Study. J. Nutr. Health Aging 11 (2007) 230-237
116. Grodstein F., Kang J.H., Glynn R.J., Cook N.R., and Gaziano J.M. A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians' Health Study II. Arch. Intern. Med. 167 (2007) 2184-2190
117. Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336 (1997) 1216-1222
118. Isaac M.G., Quinn R., and Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. Rev. (2008) CD002854
119. Dekosky S.T., Williamson J.D., Fitzpatrick A.L., et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. Jama 300 (2008) 2253-2262
120. Glenner G.G., and Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122 (1984) 1131-1135
121. Masters C.L., Multhaup G., Simms G., Pottgiesser J., Martins R.N., and Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4 (1985) 2757-2763
122. Haass C., Hung A.Y., and Selkoe D.J. Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion. J. Neurosci. 11 (1991) 3783-3793
123. Haass C. Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J. 23 (2004) 483-488
124. Lammich S., Kojro E., Postina R., et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3922-3927
125. Vassar R., Bennett B.D., Babu-Khan S., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (1999) 735-741
126. Cao X., and Sudhof T.C. Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J. Biol. Chem. 279 (2004) 24601-24611
127. Sato T., Diehl T.S., Narayanan S., Funamoto S., Ihara Y., De Strooper B., Steiner H., Haass C., and Wolfe M.S. Active gamma-secretase complexes contain only one of each component. J. Biol. Chem. 282 (2007) 33985-33993
128. Gu Y., Misonou H., Sato T., Dohmae N., Takio K., and Ihara Y. Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch. J. Biol. Chem. 276 (2001) 35235-35238
129. Qi-Takahara Y., Morishima-Kawashima M., Tanimura Y., et al. Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J. Neurosci. 25 (2005) 436-445
130. Hardy J.A., and Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256 (1992) 184-185
131. Dreses-Werringloer U., Lambert J.C., Vingtdeux V., et al. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 133 (2008) 1149-1161
132. Margallo-Lana M.L., Moore P.B., Kay D.W., et al. Fifteen-year follow-up of 92 hospitalized adults with Down's syndrome: incidence of cognitive decline, its relationship to age and neuropathology. J. Intellect. Disabil. Res. 51 (2007) 463-477
133. Yankner B.A., Dawes L.R., Fisher S., Villa-Komaroff L., Oster-Granite M.L., and Neve R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245 (1989) 417-420
134. Suzuki N., Cheung T.T., Cai X.D., et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264 (1994) 1336-1340
135. Lorenzo A., and Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 12243-12247
136. Lambert M.P., Barlow A.K., Chromy B.A., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6448-6453
137. Roychaudhuri R., Yang M., Hoshi M.M., and Teplow D.B. Amyloid beta-protein assembly and Alzheimer's disease. J. Biol. Chem 284 (2009) 4749-4753
138. Gitter B.D., Cox L.M., Rydel R.E., and May P.C. Amyloid beta peptide potentiates cytokine secretion by interleukin-1 beta-activated human astrocytoma cells. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 10738-10741
139. Jiang H., Burdick D., Glabe C.G., Cotman C.W., and Tenner A.J. beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152 (1994) 5050-5059
140. Abramov A.Y., Canevari L., and Duchen M.R. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J. Neurosci. 24 (2004) 565-575
141. Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., and Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 15 (2006) 1437-1449
142. Arispe N., Pollard H.B., and Rojas E. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10573-10577
143. Kawahara M., Arispe N., Kuroda Y., and Rojas E. Alzheimer's disease amyloid beta-protein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Biophys. J. 73 (1997) 67-75
144. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R.E. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12 (1992) 376-389
145. Rhee S.K., Quist A.P., and Lal R. Amyloid beta protein-(1-42) forms calcium-permeable, Zn2+-sensitive channel. J. Biol. Chem. 273 (1998) 13379-13382
146. Behl C., Davis J.B., Lesley R., and Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77 (1994) 817-827
147. Butterfield D.A., Drake J., Pocernich C., and Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7 (2001) 548-554
148. Goldsbury C., Whiteman I.T., Jeong E.V., and Lim Y.A. Oxidative stress increases levels of endogenous amyloid-beta peptides secreted from primary chick brain neurons. Aging Cell 7 (2008) 771-775
149. Tong Y., Zhou W., Fung V., et al. Oxidative stress potentiates BACE1 gene expression and Abeta generation. J. Neural. Transm. 112 (2005) 455-469
150. Abbott A. Neuroscience: the plaque plan. Nature 456 (2008) 161-164
151. Mandavilli A. The amyloid code. Nat. Med. 12 (2006) 747-751
152. Cullen W.K., Suh Y.H., Anwyl R., and Rowan M.J. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8 (1997) 3213-3217
153. Freir D.B., Holscher C., and Herron C.E. Blockade of long-term potentiation by beta-amyloid peptides in the CA1 region of the rat hippocampus in vivo. J. Neurophysiol. 85 (2001) 708-713
154. Stephan A., Laroche S., and Davis S. Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J. Neurosci. 21 (2001) 5703-5714
155. Chapman P.F., White G.L., Jones M.W., et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2 (1999) 271-276
156. Westerman M.A., Cooper-Blacketer D., Mariash A., et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22 (2002) 1858-1867
157. Kamenetz F., Tomita T., Hsieh H., et al. APP processing and synaptic function. Neuron 37 (2003) 925-937
158. Cirrito J.R., Yamada K.A., Finn M.B., et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48 (2005) 913-922
159. Priller C., Bauer T., Mitteregger G., Krebs B., Kretzschmar H.A., and Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J. Neurosci. 26 (2006) 7212-7221
160. Ting J.T., Kelley B.G., Lambert T.J., Cook D.G., and Sullivan J.M. Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 353-358
161. Hsieh H., Boehm J., Sato C., et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52 (2006) 831-843
162. Nusser Z., Lujan R., Laube G., Roberts J.D., Molnar E., and Somogyi P. Cell type and pathway dependence of synaptic AMPA receptor number and variability in the hippocampus. Neuron 21 (1998) 545-559
163. Takumi Y., Ramirez-Leon V., Laake P., Rinvik E., and Ottersen O.P. Different modes of expression of AMPA and NMDA receptors in hippocampal synapses. Nat. Neurosci. 2 (1999) 618-624
164. Gu Z., Liu W., and Yan Z. {beta}-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution. J. Biol. Chem. 284 (2009) 10639-10649
165. Puzzo D., Privitera L., Leznik E., et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28 (2008) 14537-14545
166. Garcia-Osta A., and Alberini C.M. Amyloid beta mediates memory formation. Learn. Mem. 16 (2009) 267-272
167. Blasko I., Jellinger K., Kemmler G., et al. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol. Aging 29 (2008) 1-11
168. Mayeux R., Honig L.S., Tang M.X., et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61 (2003) 1185-1190
169. Kern A., Roempp B., Prager K., Walter J., and Behl C. Down-regulation of endogenous amyloid precursor protein processing due to cellular aging. J. Biol. Chem. 281 (2006) 2405-2413
170. McConlogue L., Buttini M., Anderson J.P., et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J. Biol. Chem. 282 (2007) 26326-26334
171. Fukumoto H., Rosene D.L., Moss M.B., Raju S., Hyman B.T., and Irizarry M.C. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am. J. Pathol. 164 (2004) 719-725
172. Tyler S.J., Dawbarn D., Wilcock G.K., and Allen S.J. alpha- and beta-secretase: profound changes in Alzheimer's disease. Biochem. Biophys. Res. Commun. 299 (2002) 373-376
173. Stockley J.H., Ravid R., and O'Neill C. Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain. FEBS Lett. 580 (2006) 6550-6560
174. Ghersi-Egea J.F., Gorevic P.D., Ghiso J., Frangione B., Patlak C.S., and Fenstermacher J.D. Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67 (1996) 880-883
175. Shibata M., Yamada S., Kumar S.R., et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106 (2000) 1489-1499
176. Sagare A., Deane R., Bell R.D., et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 13 (2007) 1029-1031
177. Vogelgesang S., Cascorbi I., Schroeder E., et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12 (2002) 535-541
178. Deane R., Yan S.D., Submamaryan R.K., et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9 (2003) 907-913
179. Leissring M.A., Farris W., Chang A.Y., et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40 (2003) 1087-1093
180. Poirier R., Wolfer D.P., Welzl H., et al. Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit. Neurobiol. Dis. 24 (2006) 475-483
181. Hellstrom-Lindahl E., Ravid R., and Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. Neurobiol. Aging 29 (2008) 210-221
182. Russo R., Borghi R., Markesbery W., Tabaton M., and Piccini A. Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. FEBS Lett. 579 (2005) 6027-6030
183. Miners J.S., Van Helmond Z., Chalmers K., Wilcock G., Love S., and Kehoe P.G. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 65 (2006) 1012-1021